Vector Science & Therapeutics

What Vector Science & Therapeutics does

Vector Science & Therapeutics is a medical device and drug delivery platform company developing precision therapeutic systems that enable site-directed, localized drug delivery without systemic exposure. Founded in 2024 in Mequon, Wisconsin, the company became publicly traded on the TSX Venture Exchange under ticker PAIN in April 2026 following a reverse merger with OpenSesame Acquisition Corp. Its target markets span acute care, chronic musculoskeletal conditions, sports medicine, and primary care clinics, with healthcare providers and professional athletes as end customers served through both B2B enterprise sales and a sub-brand called Valor. The company is Canadian-domiciled (Vector Science & Therapeutics Inc.) and is led by CEO Bill Jackson, CFO Stephen Gledhill, and Chairman Tommy Thompson (former U.S. Secretary of Health and Human Services).

The company's core technology is built on a "Smart, Steered, Sustained" framework that combines adaptive intelligence, active site-directed delivery using iontophoresis and sonophoresis modalities, and sustained therapeutic presence. Its lead commercial platform, VectorMist™, is in pre-launch development. A provisional patent has been filed for a novel microneedle catheter platform for intratumoral drug delivery in pancreatic cancer research. Vector is developing a portfolio of 22 novel shelf-stable peptide formulations with up to 24-month stability, targeting the $80.8 billion global peptide therapeutics market. Manufacturing is conducted through a three-year development and manufacturing agreement with MPP Group LLC at a 35,000 sq. ft. FDA-registered, cGMP-compliant facility in Mequon, Wisconsin, avoiding approximately $6 million in capital expenditure, and the company has an option to acquire up to 15% of LyoGenesis Plus for up to US$1,000,000 over three years to secure long-term pharmaceutical-grade peptide manufacturing capacity.

The business model relies on commercialization of its therapeutic platforms to healthcare providers, clinicians, and clinical partners, complemented by the Valor sports medicine sub-brand, which leverages professional athlete ambassadors Gary Payton II and Dexter Fowler to drive credibility with professional sports organizations. Pricing is not publicly disclosed, and detailed platform specifications, indication scope, and commercial terms are made available only to qualified clinical partners and institutional investors. The company is pre-revenue, with VectorMist™ in pre-commercial development, and has not yet disclosed customers, contract values, or product sales.

Name

Vector Science & Therapeutics

Legal name

Vector Science & Therapeutics Inc.

Website

https://vectorscience.co

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Vector Science & Therapeutics is a Mequon-based medical device company developing precision biomechanical and active transdermal drug delivery platforms under a Smart, Steered, Sustained framework for clinicians in acute care, chronic musculoskeletal, and sports medicine markets. It trades on TSXV under PAIN.

Ownership category

akta.pro rank

Product category

Precision Drug Delivery Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Transdermal drug delivery
• Precision therapeutics
• Biomechanical medical devices
• Peptide drug formulations
• Localized drug delivery

Headquarters

HQ city

Lodi

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Platform/Product Sales: Revenue from commercialization of VectorMist™ platform and other therapeutic delivery systems to healthcare providers, clinicians, and clinical settings. The platform targets acute care (post-surgical and injury recovery) and chronic care (musculoskeletal conditions, osteoarthritis, chronic pain disorders) markets.
2. Pharmaceutical-grade Peptides: Revenue from development and manufacturing of pharmaceutical-grade peptides through their MPP Group LLC partnership. Portfolio of 22 novel shelf-stable peptide formulations targeting the $80.8 billion peptide therapeutics market.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Vector Science & Therapeutics develops and manufactures proprietary biomechanical medical devices and active transdermal drug delivery platforms that deliver site-directed therapeutics to defined anatomical targets. Its lead platform, VectorMist™, uses iontophoresis and sonophoresis modalities to enable adaptive, sustained, localized delivery without systemic exposure, targeting acute care, chronic musculoskeletal conditions, and sports medicine applications. The company also operates a Valor sports medicine division and is developing a microneedle catheter platform for intratumoral drug delivery research in pancreatic cancer.

Product overview

Vector Science & Therapeutics operates as a platform-based company developing precision therapeutic platforms built on its 'Smart, Steered, Sustained' framework. The company's first commercial platform, VectorMist™, is a precision drug delivery system currently in pre-launch development designed for clinical environments requiring site-directed, non-systemic intervention. The company has also established Valor, a sports medicine division focused on transdermal peptide delivery for soft tissue repair and athlete recovery. Both products share the core technology platform of biomechanical devices and active localized drug delivery.

Differentiator

Problem solved

Functional benefit

Brands

• VectorMist™: First commercial precision therapeutic platform bringing Smart, Steered, Sustained drug delivery framework to clinical practice for localized, non-systemic intervention.

Products and services

• VectorMist™ Platform Precision therapeutic drug delivery platform based on the Smart, Steered, Sustained framework — adaptive intelligence, active site-directed delivery (iontophoresis/sonophoresis), and sustained therapeutic presence with zero systemic exposure. Designed for clinical environments in acute care (post-surgical and injury recovery) and chronic musculoskeletal care (osteoarthritis, chronic pain disorders).
• Valor Sports Medicine Division Sports medicine division providing non-addictive injury recovery and pain management products based on transdermal peptide delivery for soft tissue repair and athlete recovery. Targets professional sports organizations and elite athletes through athlete ambassador channels.
• Microneedle Catheter Platform (Intratumoral Drug Delivery) Catheter-based platform for intratumoral drug delivery research in pancreatic cancer, integrating cell differentiation agent delivery, electrical ablation based on tumor tissue conductivity, and electrically-guided chemotherapy activation. Research-stage with a provisional patent filed.
• Pharmaceutical-Grade Shelf-Stable Peptide Formulations Portfolio of 22 novel pharmaceutical-grade peptide formulations with up to 24 months shelf stability, developed and manufactured via the MPP Group LLC partnership at an FDA-registered, cGMP-compliant facility. Designed for use with Vector's transdermal drug delivery platforms targeting the $80.8 billion global peptide therapeutics market.

Quantifiable outcome

• Up to 24 months stability for shelf-stable peptide formulations
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• LyoGenesis PluscoreStrategic or Co-development Partner · 13 May 2026Vector entered into an option agreement to acquire up to 15% equity interest in LyoGenesis Plus for up to US$1,000,000 over a three-year period. LyoGenesis Plus separately agreed to acquire MPP Group LLC, an FDA-registered, cGMP-compliant contract manufacturing organization. This transaction secures Vector long-term access to pharmaceutical-grade peptide manufacturing infrastructure.
• MPP Group LLCcoreStrategic or Co-development Partner · 11 May 2026Three-year development and manufacturing agreement to develop and manufacture pharmaceutical-grade peptides and drug delivery devices at MPP's FDA-registered, cGMP-compliant facility in Mequon, Wisconsin. Partnership supports 22 novel shelf-stable peptide formulations. Vector funds and retains ownership of dedicated manufacturing equipment representing approximately $6 million in avoided capital expenditure.
• OpenSesame Acquisition Corp.coreStrategic or Co-development Partner · 3 October 2025Definitive agreement for reverse merger, a pivotal step toward listing on the TSX Venture Exchange (TSXV) and providing access to Canadian public capital markets. The transaction was completed in April 2026.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Antares Pharma: Drug delivery device specialist in self-administered injectable and transdermal platforms (now part of Halozyme). Comparable as an established player in combination products (device + drug) targeting localized and patient-administered therapy across musculoskeletal and endocrine indications.
• Becton, Dickinson and Company (BD): Large diversified medical device and drug delivery company with significant pharmaceutical systems and delivery device franchises. Comparable as a broad incumbent in combination products and prefillable delivery systems that touches the same clinical and manufacturing ecosystem Vector is entering.
• West Pharmaceutical Services: Global leader in injectable drug containment and delivery components (elastomeric closures, prefilled syringe systems, devices). Comparable as a broad incumbent supplying the infrastructure that combination products like VectorMist™ and its microneedle catheter would integrate into.
• Halozyme Therapeutics: Commercial-stage drug delivery company (ENHANZE platform) that partners with major pharma to enable subcutaneous delivery of biologics. Comparable as a broader incumbent in enabled drug delivery, though focused on subcutaneous co-formulation rather than Vector's site-directed transdermal and intratumoral approach.
• Noven Pharmaceuticals: Established transdermal patch developer (Daytrana, Vivelle-Dot) under Viatris. Comparable as a mature incumbent in active transdermal drug delivery for site-directed therapy — the same broad category Vector is targeting with iontophoresis/sonophoresis-enabled platforms.

Emerging players

• Crinetics Pharmaceuticals: Commercial-stage peptide therapeutics company developing oral and long-acting peptide candidates for endocrine and rare disease indications. Comparable as a focused peer in the peptide therapeutics space — the same $80.8B market Vector targets with its 22-formulation shelf-stable peptide portfolio.
• DELcath Systems: Clinical and commercial company developing catheter-based, organ-specific high-dose chemotherapy delivery (PHP/CHEMOSAT) for cancers including liver-dominant metastases. Comparable as a specialized intratumoral / site-directed chemotherapy delivery peer intersecting with Vector's microneedle catheter program for pancreatic cancer.

Direct peers

• Iomed (Empi / DJO): Long-standing iontophoresis drug delivery platform for localized, non-systemic therapy in physical medicine and rehabilitation. Closely comparable to Vector's iontophoresis modality within the Smart/Steered/Sustained framework, targeting the same clinician-administered, non-opioid pain and inflammation use cases.
• ZetrOZ Systems: Developer of sustained ultrasonic (sonophoresis) drug delivery devices for musculoskeletal and soft tissue repair. Directly comparable to VectorMist™ as both companies commercialize site-directed, non-systemic therapy using ultrasound-driven transdermal delivery into the same clinical indications (tendinopathy, soft tissue injury recovery).
• RenovoRx: Clinical-stage company developing catheter-based, intratumoral drug delivery for pancreatic cancer — the same indication targeted by Vector's provisional microneedle catheter patent. Highly comparable as a peer for site-directed, minimally invasive oncology drug delivery with the goal of limiting systemic exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vector-science-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vector Science & Therapeutics